U.S. Specialty Injectable Generics Market Analysis By Therapeutic Use (Oncology, Cardiovascular, Central Nervous System, Infectious Diseases, Autoimmune Disorders), And Segment Forecasts, 2018 - 2025

Table of Contents

Chapter 1 Research Methodology & Scope
1.1 Country Market Calculation
1.1.1 Country Market: Base Estimates
1.1.2 Global Market: CAGR Calculation
1.2 List of Secondary Sources
Chapter 2 Executive Summary
2.1 Market Summary
Chapter 3 U.S. Specialty Injectable Generics Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.1.1 Market Driver Analysis
3.1.1.1 Rising number of off-patent specialty drugs
3.1.1.2 Escalating demand for low cost specialty injectable generics
3.1.1.3 Increasing prevalence of chronic diseases
3.1.1.4 Growing number of mergers and acquisitions to expand specialty injectable generics portfolio
3.1.2 Market Restraint Analysis
3.1.2.1 Stringent regulatory framework for specialty injectable generics
3.1.2.2 Adoption of risk mitigation strategies by branded drug competitors
3.2 Key Opportunities Prioritized
3.3 PET Analysis, by Factor (political & legal, economic, and technological)
3.4 Industry Analysis - Porter’s Five Forces Analysis
3.5 U.S. Specialty Injectable Generics Market: Company Market Share Analysis, 2016
3.6 Patent Analysis
3.7 Pricing Trend Analysis, 2016
Chapter 4 U.S. Specialty Injectable Generics Market: Therapeutic Use Estimates & Trend Analysis
4.1 U.S. specialty injectable generics market: Therapeutic use movement analysis
4.2 Oncology
4.2.1 Oncology market, 2014 - 2025 (USD Billion)
4.3 Cardiovascular
4.3.1 Cardiovascular market, 2014 - 2025 (USD Billion)
4.4 CNS
4.4.1 CNS market, 2014 - 2025 (USD Billion)
4.5 Infectious Diseases
4.5.1 Infectious diseases market, 2014 - 2025 (USD Billion)
4.6 Autoimmune Disorders
4.6.1 Autoimmune disorders market, 2014 - 2025 (USD Billion)
4.7 Others
4.7.1 Others market, 2014 - 2025 (USD Billion)
Chapter 5 Competitive Landscape
5.1 Strategy framework
5.2 Market participation categorization
5.3 Market participation categorization
5.4 Company Profiles
5.4.1 Pfizer, Inc.
5.4.1.1 Company overview
5.4.1.2 Financial performance
5.4.1.3 Product benchmarking
5.4.1.4 Strategic initiatives
5.4.2 Teva Pharmaceutical Industries Ltd.
5.4.2.1 Company overview
5.4.2.2 Financial performance
5.4.2.3 Product benchmarking
5.4.2.4 Strategic initiatives
5.4.3 Novartis AG
5.4.3.1 Company overview
5.4.3.2 Financial performance
5.4.3.3 Product benchmarking
5.4.3.4 Strategic initiatives
5.4.4 Mylan N.V.
5.4.4.1 Company overview
5.4.4.2 Financial performance
5.4.4.3 Product benchmarking
5.4.4.4 Strategic initiatives
5.4.5 Uman Pharma
5.4.5.1 Company overview
5.4.5.2 Product benchmarking
5.4.5.3 Strategic initiatives
5.4.6 Fresenius SE & Co. KGaA
5.4.6.1 Company overview
5.4.6.2 Financial performance
5.4.6.3 Product benchmarking
5.4.6.4 Strategic initiatives
5.4.7 Baxter
5.4.7.1 Company overview
5.4.7.2 Financial performance
5.4.7.3 Product benchmarking
5.4.7.4 Strategic initiatives
5.4.8 Par Pharmaceutical
5.4.8.1 Company overview
5.4.8.2 Financial performance
5.4.8.3 Product benchmarking
5.4.8.4战略initiatives
5.4.9 Sagent Pharmaceuticals, Inc.
5.4.9.1 Company overview
5.4.9.2 Financial performance
5.4.9.3 Product benchmarking
5.4.9.4 Strategic initiatives
5.4.10 Teligent
5.4.10.1 Company overview
5.4.10.2 Financial performance
5.4.10.3 Product benchmarking
5.4.10.4 Strategic initiatives
5.4.11 Hikma Pharmaceuticals PLC
5.4.11.1 Company overview
5.4.11.2 Financial performance
5.4.11.3 Product benchmarking
5.4.11.4 Strategic initiatives

List of Tables

TABLE 1 U.S. specialty injectable generics market, by therapeutic use, 2014 - 2025 (USD Billion)

List of Figures

FIG. 1 Market summary
FIG. 2 Market trends & outlook
FIG. 3 Market segmentation& scope
FIG. 4 Market driver relevance analysis (Current & future impact)
FIG. 5 Market restraint relevance analysis (Current & future impact)
FIG. 6 Key opportunities prioritized
FIG. 7 PET Analysis, by Factor (political & legal, economic, and technological)
FIG. 8 U.S. Specialty Injectable Generics - Porter’s Five Forces Analysis
FIG. 9 Company market share analysis, 2016
FIG. 10 U.S. specialty injectable generics market, therapeutic use outlook: key takeaways
FIG. 11 U.S. specialty injectable generics market: Therapeutic use movement analysis
FIG. 12 U.S. oncology market, 2014 - 2025 (USD Billion)
FIG. 13 U.S. cardiovascular market, 2014 - 2025 (USD Billion)
FIG. 14 U.S. CNS market, 2014 - 2025 (USD Billion)
FIG. 15 U.S. infectious diseases market, 2014 - 2025 (USD Billion)
FIG. 16 U.S. autoimmune disorders market, 2014 - 2025 (USD Billion)
FIG. 17 U.S. others market, 2014 - 2025 (USD Million)
FIG. 18 Strategy framework
FIG. 19 Participant categorization